Literature DB >> 22890369

The role of macular hydration in the evaluation of the effect of intravitreal triamcinolone on visual acuity in eyes with diabetic macular edema.

Kenan Sonmez1, Tongalp H Tezel, Henry J Kaplan.   

Abstract

To evaluate the efficacy of intravitreal triamcinolone (IVTA) in eyes with clinically definite diabetic macular edema (DME) by using the parameters visual acuity (VA), central macular thickness (CMT) and macular hydration (MH). Medical records of patients who received IVTA (4 mg/0.1 mL) for DME were reviewed. Optically non-reflective areas which appear dark spaces within the 1000 μm from the center of the macula on OCT scan defined as MH. Best corrected logarithm of minimum angle of resolution (logMAR) visual acuity, CMT as determined by optical coherence tomography (OCT) and MH quantified from the OCT scans by using metamorph analysis were evaluated before the injection and at 1, 3 and 6 months in all, and up to 12 months in some eyes, after the IVTA injection. The correlations between these variables were also studied. 28 eyes of 27 patients were included in the study. Eyes with DME treated by a single IVTA injection responded with a trend towards significant improvement in logMAR VA at 1 (p < 0.0001) and 3 months (p < 0.0001), but no significant improvement in relation to baseline at 6 months was observed (p = 0.07). CMT was significantly reduced at 1 month (p < 0.0001), 3 months (p < 0.0001) and 6 months (p = 0.01) compared to baseline. Like the trend observed in VA improvement, MH also significantly reduced at 1 month (p < 0.0001) and 3 months (p < 0.0001), but not at 6 months (p = 0.14) compared to baseline. There was no correlation between the VA ratio and the CMT ratio (r = 0.18, p = 0.36), but there was a significant correlation between the VA ratio and the MH ratio (r = 0.85, p < 0.0001). There was also an inverse relationship between MH ratio and the age of the patients (r = -0.7089, p = 0.0001). Macular hydration seems to be a better parameter than macular thickness for determining the effectiveness of IVTA treatment in a subset of eyes with DME. Although the treatment effect is temporary, younger patients with DME were more prone to respond with a greater reduction in MH after IVTA injection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890369     DOI: 10.1007/s10792-012-9617-2

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  30 in total

1.  Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid.

Authors:  S D Pendergast; T S Hassan; G A Williams; M S Cox; R R Margherio; P J Ferrone; B R Garretson; M T Trese
Journal:  Am J Ophthalmol       Date:  2000-08       Impact factor: 5.258

2.  Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.

Authors:  A P Ciardella; J Klancnik; W Schiff; G Barile; K Langton; S Chang
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

3.  Imaging of macular diseases with optical coherence tomography.

Authors:  C A Puliafito; M R Hee; C P Lin; E Reichel; J S Schuman; J S Duker; J A Izatt; E A Swanson; J G Fujimoto
Journal:  Ophthalmology       Date:  1995-02       Impact factor: 12.079

4.  Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.

Authors:  J B Jonas; A Söfker
Journal:  Am J Ophthalmol       Date:  2001-09       Impact factor: 5.258

Review 5.  Macular edema. A complication of diabetic retinopathy.

Authors:  F L Ferris; A Patz
Journal:  Surv Ophthalmol       Date:  1984-05       Impact factor: 6.048

6.  Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema.

Authors:  Roy W Beck; Allison R Edwards; Lloyd P Aiello; Neil M Bressler; Frederick Ferris; Adam R Glassman; Elizabeth Hartnett; Michael S Ip; Judy E Kim; Craig Kollman
Journal:  Arch Ophthalmol       Date:  2009-03

7.  The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

8.  A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema.

Authors:  Mohammad H Dehghan; Hamid Ahmadieh; Alireza Ramezani; Morteza Entezari; Arash Anisian
Journal:  Int Ophthalmol       Date:  2007-06-23       Impact factor: 2.031

9.  Intravitreal injection of triamcinolone for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Ingrid Kreissig; Antje Söfker; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2003-01

10.  Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results.

Authors:  C M Lee; R J Olk
Journal:  Ophthalmology       Date:  1991-10       Impact factor: 12.079

View more
  1 in total

Review 1.  Updates in the management of diabetic macular edema.

Authors:  Christopher Mathew; Anastasia Yunirakasiwi; Srinivasan Sanjay
Journal:  J Diabetes Res       Date:  2015-04-23       Impact factor: 4.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.